Clinical Trial: To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054970) titled 'To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects' on June 22.

Brief Summary: This is a Phase 1, Randomized, Double-blind, three-arm, Parallel group, Single-dose Study to Compare the Pharmacokinetics, Safety and immunogenicity of CT-P55, EU-approved Cosentyx and US-licensed Cosentyx in Healthy male Subjects

Study Start Date: Jan. 12, 2024

Study Type: INTERVENTIONAL

Condition: Healthy Male Subjects

Intervention: BIOLOGICAL: CT-P55

150 mg in 1.0 mL, administered as a single SC injection via PFS

BIOLOGICAL: US-licensed Cosentyx

150 mg in 1.0 mL, administered as a single SC inj...